EUVIMEDEUVIMED entdecken
Open Access

Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia

Michael J Vinikoor iD, Kalongo Hamusonde, Guy Muula, Mah Asombang, Carlotta Riebensahm, Helen Chitundu, Veronica Sunkuntu-Sichizya, Debika Bhattacharya, Edford Sinkala, Georg Lauer, Raymond Chung, Wilson Mbewe und 3 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Michael J Vinikoor und 14 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Coinfection, Viral Load. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIAID NIH HHS, FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term outcomes of tenofovir-containing antiretroviral therapy (ART) for hepatitis B virus (HBV)/human immunodeficiency virus (HIV) coinfection were evaluated in Zambia.

Methods

A prospective cohort of adults with HIV and hepatitis B surface antigen (HBsAg)-positivity was enrolled at ART initiation. On tenofovir-containing ART, we ascertained HBV viral load (VL) non-suppression, alanine aminotransferase (ALT) elevation, serologic end-points, progression of liver fibrosis based on elastography, and hepatocellular carcinoma (HCC) incidence. We also described a subgroup (low HBV VL and no/minimal fibrosis at baseline) that, under current international guidelines, would not have been treated in the absence of their HIV infection.

Results

Among 289 participants at ART start, median age was 34 years, 40.1% were women, median CD4 count was 191 cells/mm3, 44.2% were hepatitis B e antigen-positive, and 28.4% had liver fibrosis/cirrhosis. Over median 5.91 years of ART, 13.6% developed HBV viral non-suppression, which was associated with advanced HIV disease. ALT elevation on ART was linked with HBV VL non-suppression. Regression of fibrosis and cirrhosis were common, progression to cirrhosis was absent, and no cases of HCC were ascertained. HBsAg seroclearance was 9.4% at 2 and 15.4% at 5 years, with higher rates among patients with low baseline HBV replication markers.

Conclusions

Reassuring long-term liver outcomes were ascertained during tenofovir-based ART for HBV/HIV coinfection in Zambia. Higher than expected HBsAg seroclearance during ART underscores the need to include people with HIV in HBV cure research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsCoinfectionViral LoadLiver CirrhosisHepatitis BHumansFemaleMaleAdultZambiaProspective StudiesCarcinoma, HepatocellularTreatment OutcomeLiver NeoplasmsAnti-HIV AgentsHepatitis B Surface AntigensMiddle AgedHepatitis B virus

Stichwörter der Autor:innen

HIV/AIDSantiviral therapyhepatitis Bhepatocellular carcinomaliver fibrosis

Substanzen

TenofovirAnti-HIV AgentsHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Research Department, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.
  • Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • School of Medicine, University of Zambia, Lusaka, Zambia.
  • Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
  • Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Radiology, University Teaching Hospital, Lusaka, Zambia.

ORCID-Profile: Michael J Vinikoor

Förderung

  • NICHD NIH HHS
  • NIAID NIH HHS
  • FIC NIH HHS
  • Swiss National Science Foundation
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Vinikoor, M. J., Hamusonde, K., Muula, G., Asombang, M., Riebensahm, C., Chitundu, H., Sunkuntu-Sichizya, V., Bhattacharya, D., Sinkala, E., Lauer, G., Chung, R., Mbewe, W., Egger, M., Bosomprah, S., & Wandeler, G. (2024). Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad654

Vancouver

Vinikoor MJ, Hamusonde K, Muula G, Asombang M, Riebensahm C, Chitundu H, et al. Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad654

BibTeX
@article{Vinikoor2024,
  author = {Vinikoor, Michael J and Hamusonde, Kalongo and Muula, Guy and Asombang, Mah and Riebensahm, Carlotta and Chitundu, Helen and Sunkuntu-Sichizya, Veronica and Bhattacharya, Debika and Sinkala, Edford and Lauer, Georg and Chung, Raymond and Mbewe, Wilson and Egger, Matthias and Bosomprah, Samuel and Wandeler, Gilles},
  title = {Long-term Hepatitis B and Liver Outcomes Among Adults Taking Tenofovir-Containing Antiretroviral Therapy for HBV/HIV Coinfection in Zambia},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad654}
}
Kostenlos starten →